Why trials for remdesivir but not for hydroxychloroquine?
The FDA and the media continue to characterize hydroxychloroquine as a dangerous unknown because full clinical trials for its use in treating COVID-19 have not been done.
Yet the FDA eagerly promotes remdesivir, whose safety and efficacy are far less clear.
All drugs have side effects, but hydroxychloroquine has been used widely for decades to treat other diseases, so its safety profile is well known, unlike remdesivir.
Oops! An active online subscription is required to access this content.
Please login below or Subscribe today!